Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Net Cash Flow (2018 - 2025)

Bicycle Therapeutics' Net Cash Flow history spans 8 years, with the latest figure at -$19.9 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 108.5% year-over-year to -$19.9 million; the TTM value through Dec 2025 reached -$252.2 million, down 171.27%, while the annual FY2025 figure was -$252.2 million, 171.27% down from the prior year.
  • Net Cash Flow reached -$19.9 million in Q4 2025 per BCYC's latest filing, up from -$71.9 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $504.6 million in Q2 2024 to a low of -$87.0 million in Q1 2025.
  • Average Net Cash Flow over 5 years is $24.7 million, with a median of -$22.9 million recorded in 2022.
  • Peak YoY movement for Net Cash Flow: crashed 1200.46% in 2022, then soared 2780.59% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at $179.2 million in 2021, then crashed by 114.44% to -$25.9 million in 2022, then crashed by 81.5% to -$47.0 million in 2023, then skyrocketed by 79.64% to -$9.6 million in 2024, then crashed by 108.5% to -$19.9 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Net Cash Flow are -$19.9 million (Q4 2025), -$71.9 million (Q3 2025), and -$73.3 million (Q2 2025).